Abstract
Five analogs of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] [1], 26,27-dimethyl-1α,25-dihydroxyvitamin D3 [1,25(OH)2(Me)2D3] [2], 26,27-dimethyl-1α,25-dihydroxyvitamin D3 [1,25(OH)2(Et)2D3] [3], 26,27-dipropyl-1α, 25-dihydroxyvitamin D3 [1,25(OH)2(Pr)2D3] [4], 26,27-dimethyl-24, 24-difluoro-1α,25-dihydroxyvitamin D3 [24F2-1,25(OH)2(Me)2D3, and [5] 24a-homo-24,24-difluoro-1α,25-dihydroxyvitamin D3 [24aF2-homo-1,25(OH)2D3] were investigated to clarify the possibility that prevents osteopenia induced in rats by ovariectomy and sciatic neurotomy. The objective of our studies was to determine whether these analogs may be effective for treatment of subjects with osteoporosis. 1,25(OH)2(Me)2D3, 24F2-1,25(OH)2(Me)2D3, and 24aF2-homo-1,25(OH)2D3 prevented decreases in bone mineral density (BMD) of the femur, as measured by dual energy X-ray absorptiometry (DXA). The potency of 1,25(OH)2(Me)2D3 in this test was higher than that of 1,25(OH)2D3. The potencies of 24F2-1,25(OH)2(Me)2D3 and 24aF2-homo-1,25(OH)2D3 were similar to that of 1,25(OH)2D3. On the other hand, though 1,25(OH)2(Et)2D3 and 1,25(OH)2(Pr)2D3 had a preventive effect on the decease in BMD, the potency of two analogs was lower than that of 1,25(OH)2D3. Decreases in cortical and trabecular bone areas of the femur were prevented by three analogs of 1,25(OH)2D3, 1,25(OH)2(Me)2D3, 24F2-1,25(OH)2(Me)2D3, and 24aF2-homo-1,25(OH)2D3. Serum calcium (Ca) concentration was elevated at the last administration of three analogs of 1,25(OH)2D3, 1,25(OH)2(Me)2D3, 24F2-1,25(OH)2(Me)2D3 and 24aF2-homo-1,25(OH)2D3. Decreases in the Ca concentration in untreated rats were noted a few days after the last administration. In light of these positive effects, we are continuing research on 1,25(OH)2(Me)2D3, 24F2-1,25(OH)2(Me)2D3, and 24aF2-homo-1,25(OH)2D3 as putative treatment for osteoporosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DeLuca HF, Schones HK (1983) Vitamin D: recent advances. Annu Rev Biochem 52:411
Matsumoto T, Igarashi C, Takeuchi Y, Harada S, Kikuchi T, Yamato H, Ogata E (1991) Stimulation by 1α,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC-3T3-E1 cells. Bone 12:27–32
Caniggia A, Nuti R, Lore F, Vattimo A (1985) 1,25(OH)2 Vitamin D3 in the long-term treatment of post-menopausal osteoporosis. In: Vitamin D. A chemical, biochemical and clinical update. Walter de Gruyter, Berlin, New York, pp 986–995
Lindgren V, DeLuca HF (1982) Role of parathyroid hormone and 1,25-dihydroxyvitamin D3 in the development of osteopenia oophorectomized rats. Calcif Tissue Int 34:510–514
Okumura H, Yamamuro R, Kasai R, Hayashi T, Tada K, Nishii Y (1987) Effect of 1α-hydroxyvitamin D3 on osteoporosis induced by immobilization combined with ovariectomy in rats. Bone 8:351–355
Lindgren JU, Johnell O, DeLuca HF (1983) Studies of bone tissue in rats treated by prednisolone and 1,25(OH)2D3. Clin Orthop 181:264–268
Gill HS, Londowski JM, Corrodino RA, Zmsmeister AR, Kumar R (1988) The synthesis and biological activity of 25-dihydroxy-26,27-dimethylvitamin D and 1,25-dihydroxy-26,27-dimethylvitamin D: highly potent novel analogs of vitamin D. J Steroid Biochem 31:147–160
Eguchi T, Ikekawa N, Sumitani K, Kumegawa M, Higuchi S, Otomo S (1990) Effect on carbon lengthening at the side chain terminal of 1α,25-dihydroxyvitamin D3 for calcium regulating activity. Chem Pharm Bull 38:1246–1249
Okamoto S, Tanaka Y, DeLuca HF, Kobayashi Y, Ikekawa N (1983) Biological activity of 24,24-difluoro-1,25-dihydroxyvitamin D3. Am J Physiol 244:E159-E163
Tanaka Y, DeLuca HF, Kobayashi Y, Ikekawa N (1984) 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3: a highly potent, long-lasting analog of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 229:335–348
Okumura H, Yamamuro T, Higuchi S, Harada M, Takamura T, Otomo S, Aihara H, Ikekawa N, Kobayashi T (1990) 26,27-hexa-fluoro-1,25-dihydroxyvitamin D3 (F6-1,25(OH)2D3) prevents osteoporosis induced by immobilization combined with ovariectomy in the rat. Bone Miner 9:101–109
Miyahara T, Harada M, Miyata M, Sugure A, Ikemoto Y, Takamura T, Higuchi S, Otomo S, Kozuka H, Ikekawa N (1992) Calcium regulating activity of 26,27-dialkyl analogs of 1,25-dihydroxyvitamin D3. Calcif Tissue Int 51:218–223
Harada M, Miyahara T, Miyata M, Komiyama H, Sugure A, Ikemoto Y, Kondo S, Takamura T, Higuchi S, Otomo S, Kozuka H, Ikekawa N (1993) Calcium regulating activity of 24a-homo-24,24-difluoro-1,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1,25-dihydroxyvitamin D3. Calcif Tissue Int 53:318–323
Ikekawa N, Eguchi T, Hara N, Takatsuto S, Honda A, Mori Y, Otomo S (1987) 26,27-diethyl-1α,25-dihydroxyvitamin D3 and 24,24-difluoro-24-homo-1α,25-dihydroxyvitamin D3: highly potent inducer for differentiation of human leukemia cells HL-60. Chem Pharm Bull 35:4362–4365
Connerty HV, Briggs AR (1966) Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol 45:290–296
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harada, M., Takamura, T., Kajita-Kondo, S. et al. Elongation of the side chain of analogs of 1α,25-dihydroxyvitamin D3 prevents osteopenia in a rat model. Calcif Tissue Int 56, 220–226 (1995). https://doi.org/10.1007/BF00298614
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00298614